Previous 10 | Next 10 |
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing -- Interim results from the Phase 1 study show a favorable safety and tolerability profile wit...
Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency - Event to be webcast live on Tuesday, October 12, 2021, at 5:30 a.m. PT - PR Newswire ...
Inhibrx (NASDAQ:INBX): Q2 GAAP EPS of -$0.55 beats by $0.01. Revenue of $0.95M beats by $0.13M. Press Release For further details see: Inhibrx EPS beats by $0.01, beats on revenue
Inhibrx Reports Second Quarter 2021 Financial Results PR Newswire SAN DIEGO , Aug. 9, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the second quarter of...
Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford - Median progression-free survival (PFS) of 7.6 months and disease cont...
Two new sample breakout stocks for Week 24 with better than 10% short-term upside potential. This past week the peak gains were in LIZI +28.9% and LQDT +10.3% with all 4 picks giving back gains to the Friday close on higher negative MG® conditions. 2021 MDA minimal portfolio ...
Inhibrx Announces Participation in Upcoming Investor Conferences PR Newswire SAN DIEGO , May 17, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candida...
Inhibrx (INBX): Q1 GAAP EPS of -$0.51 beats by $0.08.Revenue of $0.89M (+2.3% Y/Y) misses by $0.04M.Press Release For further details see: Inhibrx EPS beats by $0.08, misses on revenue
Inhibrx Reports First Quarter 2021 Financial Results PR Newswire SAN DIEGO , May 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter...
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-07-23 06:30:08 ET JMP Securities analyst issues MARKET PERFORM recommendation for INBX on July 23, 2024 04:40AM ET. The previous analyst recommendation was Outperform. INBX was trading at $13.49 at issue of the analyst recommendation. The overall analyst consensus :...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...